The disposition and metabolism of GW695634: A non-nucleoside reverse transcriptase inhibitor (NNRTi) for treatment of HIV/AIDS

References

• Becker S, Lelezari J, Walworth C, Kumar P, Cade J, Ng-Cashin J, Kim Y, Scott J, St. Clair M, Jones L, Symonds W. (2006). Antiviral activity and safety of GW695634, a novel next generation NNRTI in NNRTI-resistant HIV-1 infected patients. International Aids Society-Rio. Poster MoPl01.
   Google Scholar
• Borrás-Blasco J, Navarro-Ruiz A, Borrás C, Casterá E. (2008). Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection. J Antimicrob Chemother 62:879–888.
   PubMedGoogle Scholar
• Cho A. (2006). Recent advances in oral prodrug discovery. Annual Reports in Medicinal Chemistry. Vol. 41: pp. 395–405.
   Google Scholar
• Chan J, Freeman G, Tidwell J, Romines K, Schaller l, Cowan J, Gonzales S, Lowell G, Andrews C, Reynolds D, St. Clair M, Hazen R, Ferris R, Creech K, Roberts G, Short S, Weaver K, Koszalka G, Boone L. (2004). Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem 47:1175–1182.
   PubMed Web of Science ®Google Scholar
• Dieterich DT, Robinson PA, Love J, Stern JO. (2004). Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clin Infect Dis 38 Suppl 2:S80–S89.
   Google Scholar
• Ferris RG, Hazen RJ, Roberts GB, St Clair MH, Chan JH, Romines KR, Freeman GA, Tidwell JH, Schaller LT, Cowan JR, Short SA, Weaver KL, Selleseth DW, Moniri KR, Boone LR. (2005). Antiviral activity of GW678248, a novel benzophenone nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother 49:4046–4051.
   PubMed Web of Science ®Google Scholar
• Hazen RJ, Harvey RJ, St Clair MH, Ferris RG, Freeman GA, Tidwell JH, Schaller LT, Cowan JR, Short SA, Romines KR, Chan JH, Boone LR. (2005). Anti-human immunodeficiency virus type 1 activity of the nonnucleoside reverse transcriptase inhibitor GW678248 in combination with other antiretrovirals against clinical isolate viruses and in vitro selection for resistance. Antimicrob Agents Chemother 49:4465–4473.
   PubMed Web of Science ®Google Scholar
• Kim Y, Symonds W, Steel H, Ng-Cashin J, Moore K. (2004). Safety and pharmacokinetics (PK) of 695634 following repeat oral dose administration to healthy subjects. 44th Interscience Conference on Antimicrobial Agents Chemotherapy. Poster A-23.
   Google Scholar
• Lazzarin A, Campbell T, Clotet B, Johnson M, Katlama C, Moll A, Towner W, Trottier B, Peeters M, Vingerhoets J, de Smedt G, Baeten B, Beets G, Sinha R, Woodfall B. (2007). Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 370:39–48.
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1, 2009; 1–161. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
   Google Scholar
• Pauwels R. (2004). New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infections. Curr Opin Pharmacol 4:437–446.
   PubMed Web of Science ®Google Scholar
• Pérez-Molina JA. (2002). Safety and tolerance of efavirenz in different antiretroviral regimens: Results from a national multicenter prospective study in 1,033 HIV-infected patients. HIV Clin Trials 3:279–286.
   PubMedGoogle Scholar
• Romines KR, Freeman GA, Schaller LT, Cowan JR, Gonzales SS, Tidwell JH, Andrews CW 3rd, Stammers DK, Hazen RJ, Ferris RG, Short SA, Chan JH, Boone LR. (2006). Structure-activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitor. J Med Chem 49:727–739.
   PubMed Web of Science ®Google Scholar
• Sanne I, Mommeja-Marin H, Hinkle J, Bartlett JA, Lederman MM, Maartens G, Wakeford C, Shaw A, Quinn J, Gish RG, Rousseau F. (2005). Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis 191:825–829.
   PubMed Web of Science ®Google Scholar
• Sluis-Cremer N, Temiz NA, Bahar I. (2004). Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding. Curr HIV Res 2:323–332.
   PubMed Web of Science ®Google Scholar
• Schaller L, Burnette T, Cowan J, Feldman P, Freeman G, Marr H, Owens B, Romines K, Shepard J, Boone L, Chan J. (2003). Abstract. 43rd Interscience Conference on Antimicrobal Agents Chemotherapy. Poster H-872.
   Google Scholar